Abstract
Evening-dosed HLD200 is a delayed-release and extended-release methylphenidate (DR/ER-MPH) designed to provide treatment effect from the time of waking and throughout the day. A pivotal phase 3 study of DR/ER-MPH in children with ADHD demonstrated significant improvements in ADHD symptoms and functional impairment, with ADHD symptoms measured by the ADHD Rating Scale-IV (ADHD-RS-IV) in the 6-week, open-label, treatment-optimization phase of the study (ClinicalTrial NCT02493777). This post hoc analysis sought to determine the clinical significance of these findings by applying established clinical thresholds of response to the ADHD-RS-IV scores reported in the trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
